Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 672 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Fatty Liver Disease Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
View directory record Official record
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Results available

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT04897594
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 7, 2026, 12:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222
View directory record Official record
Conditions
NASH, Cirrhosis, Liver
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Completed No phase listed Observational

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT00326482
View directory record Official record
Conditions
Liver Fibrosis, Steatohepatitis, Elevated Transaminases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER

NCT04165343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram, Blood test
Radiation · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease

NCT03839082
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Interventions
Usual Care then FitBit, FitBit then Usual Care
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Study of Losartan in the Treatment of NAFLD in Children

NCT01913470
View directory record Official record
Conditions
NAFLD
Interventions
Losartan
Drug
Lead sponsor
Miriam Vos, MD
Other
Eligibility
11 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 7, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
View directory record Official record
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 7, 2026, 12:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 7, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03676231
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SGM-1019, Placebo
Drug
Lead sponsor
Second Genome
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

NCT06675929
View directory record Official record
Conditions
Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions
BI 770371, Placebo for BI 770371
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Coronado, California • Montclair, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Not applicable Interventional

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

NCT06215131
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
Interventions
In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 7, 2026, 12:23 AM EDT
Recruiting No phase listed Observational

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

NCT05462574
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions
No Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Early Phase 1 Interventional Results available

Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease

NCT00949403
View directory record Official record
Conditions
Fatty Liver
Interventions
Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 7, 2026, 12:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

NCT05209100
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Sigmoidoscopy
Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
35 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739
View directory record Official record
Conditions
NAFLD
Interventions
RYI-018, Placebo
Biological
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 7, 2026, 12:23 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members

NCT01643512
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 7, 2026, 12:23 AM EDT
Terminated Phase 2 Interventional Results available

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204
View directory record Official record
Conditions
Diabetes Complications, Fatty Liver
Interventions
exenatide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
Drug
Lead sponsor
Oasis Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Oral Proglumide for NASH

NCT04152473
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Proglumide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT05327127
View directory record Official record
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 7, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study in NASH to Assess IVA337

NCT03008070
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Madison, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 7, 2026, 12:23 AM EDT